Back

Diabetes mellitus and cardiovascular mortality across the spectrum of aortic stenosis

29 August 2022 (12:15 - 12:55)
Organised by:
Congress Presentation Part of: Epidemiology, prognosis, course, and outcome of valvular heart disease Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Augustin Coisne

Lille University Hospital, Lille (France)

5 More presentations in this session

Presentation thumbnail
Tricuspid regurgitation: frequency, management and outcome among patients with severe left-sided valvular heart disease in Europe. Insights from the ESC-EORP valvular heart disease II survey
Doctor J. Dreyfus (Saint-Denis, FR)
Abstract Slides
Presentation thumbnail
Outcomes benefit in asymptomatic patients with moderate aortic valve stenosis followed up in heart valve clinics
Doctor P. Paolisso (Rome, IT)
Abstract Slides
Presentation thumbnail
Heritability and environmental influences on the onset of aortic valve sclerosis: a twin population study
Doctor P. Poggio (Milan, IT)
Abstract Slides
Presentation thumbnail
The long-term clinical course of moderate tricuspid regurgitation
Doctor D. Margonato (Milan, IT)
Abstract Slides
Presentation thumbnail
Modeling aortic stenosis progression: impact on follow-up, treatment and survival
Doctor R. Teixeira (Vila Nova de Gaia, PT)
Abstract Slides

Access the full session

Session thumbnail
Epidemiology, prognosis, course, and outcome of valvular heart disease

The Event

Event poster

ESC Congress 2022

29 August 2022 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Sex-related disparities in prognosis and clinical progression in patients with type 2 diabetes and degenerative aortic stenosis
1 September 2025
thumbnail
Congress Presentation
Diabetes and myocardial fibrosis: a systematic review and meta-analysis
29 June 2021
thumbnail
Congress Presentation
All-cause mortality and cardiovascular death in 52091 patients with hypertrophic cardiomyopathy. A nationwide cohort study
27 August 2021
thumbnail
Congress Presentation
Impact of SGLT2 inhibitor on mortality and cardiovascular outcomes in patients with type 2 diabetes mellitus with left main or multivessel coronary artery disease
27 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources